Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin
AIDS Research and Human Retroviruses Jul 2016, Vol. 32, No. 7: 660-667. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - June 26, 2016 Category: Infectious Diseases Authors: Tess PetersenYu-Jin LeeAnu OsinusiValerianna K. AmorosaCrystal WangMinhee KangRoy MatiningXiao ZhangDiana DouTriin UmblejaShyam KottililMarion G. Peters Source Type: research
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon and Cytokine Research)
Source: Journal of Interferon and Cytokine Research - June 20, 2016 Category: Molecular Biology Authors: Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan Source Type: research
Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
Journal of Interferon & Cytokine Research , Vol. 0, No. 0. (Source: Journal of Interferon)
Source: Journal of Interferon - June 20, 2016 Category: Research Authors: Robert FlisiakSeiji KawazoeOlga ZnoykoNimer AssyAdrian GadanoJia-Horng KaoKwan-Sik LeeRicardo ZwirtesSimon PortsmouthYuping DongDong XuHiromitsu KumadaSubasree Srinivasan Source Type: research
Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a.
CONCLUSION: IFN treatment results in HBsAg loss and seroconversion in a considerable proportion of inactive HBsAg carriers with low HBsAg concentrations.
PMID: 27239256 [PubMed] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - June 1, 2016 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Na ïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
Conclusion < /h3 > < p class= " a-plus-plus " > High SVR12 rates can be achieved with boceprevir plus peginterferon alfa-2a/ribavirin in treatment-na ïve HCV genotype 1 patients, including patients with well-compensated cirrhosis. Treatment is well tolerated when label restrictions are taken into account. < /p > < /span > < span class= " a-plus-plus abstract-section id-a-sec5 " > < h3 class= " a-plus-plus " > Trial Registration Number < /h3 > < p class= " a-plus-plus " > ClinicalTrials.gov Identifier: NCT01591460. < /p > < /span > < span class= " a-plus-plus abstract-section id-a-sec6 " > < h3 class= " a-plus-plus " > Fun...
Source: Infectious Diseases and Therapy - May 31, 2016 Category: Infectious Diseases Source Type: research
Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1 Patients: International Phase IIIb/IV TriCo Trial
Conclusion
High SVR12 rates can be achieved with boceprevir plus peginterferon alfa-2a/ribavirin in treatment-naïve HCV genotype 1 patients, including patients with well-compensated cirrhosis. Treatment is well tolerated when label restrictions are taken into account.
Trial Registration Number
ClinicalTrials.gov Identifier: NCT01591460.
Funding
F. Hoffmann-La Roche Ltd. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - May 25, 2016 Category: Infectious Diseases Source Type: research
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
CONCLUSION: Addition of faldaprevir to PegIFN/RBV increased SVR12 in patients with HCV genotype-1, and was well tolerated. Faldaprevir 120 mg is effective in the treatment of HCV genotype-1. ClinicalTrials.gov: NCT01343888 and NCT01297270.
PMID: 27049487 [PubMed - as supplied by publisher] (Source: Annals of Hepatology)
Source: Annals of Hepatology - April 8, 2016 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys): TRACES Study
Abstract: Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type.
We collected data from 439 patients (HBeAg positive, n = 349; HBeAg negative, n = 90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) we...
Source: Medicine - April 1, 2016 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
CONCLUSION: Daclatasvir plus pegIFN/RBV demonstrated noninferiority to telaprevir plus pegIFN/RBV for SVR12 and was well-tolerated in treatment-naive GT1b-infected patients, supporting the use of daclatasvir with other direct-acting antivirals.
PMID: 27022224 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - March 27, 2016 Category: Gastroenterology Authors: Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin P Tags: World J Gastroenterol Source Type: research
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects.
We describe their specific properties, such as their stability, solubility, mean of administration or targeting, distribution, metabolism and toxicity. We discuss their categorization as medical devices or drugs, their fabrication process within a regulatory environment as well as intellectual property and financial aspects that are all essential to enable their industrial development.
PMID: 26402250 [PubMed - in process] (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - February 17, 2016 Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis
Conclusions
Treatment with danoprevir/r-based regimens for 24 weeks is safe and well tolerated in CHC patients with compensated cirrhosis. A quadruple therapy regimen (danoprevir/r, mericitabine, peginterferon alfa/ribavirin) produced high SVR24 rates in prior null responders, particularly among G1b patients. (Source: Hepatology International)
Source: Hepatology International - February 17, 2016 Category: Infectious Diseases Source Type: research
Peginterferon alfa-2
Interferons alfa-2a and -2b are biosynthetic forms of interferon alfa and consist of 165 amino acids. Interferons alfa-2a and -2b differ at amino acid position 23; alfa-2a has a lysine in that position, whereas -2b has an arginine at that position. Compared to other interferon alfa subtypes, interferons alfa-2a and -2b both have a deletion at position 44 in the amino acid sequence. [#] Peginterferon alfa-2a is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethlyene glycol (PEG) chain. The PEG moiety is linked at a single site via a stable amide bond to lysine. Peginterfero...
Source: Aids Info Drugs - February 16, 2016 Category: Drugs & Pharmacology Source Type: research
Combination of Tenofovir Disoproxil Fumarate and Peginterferon alfa-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B
Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon alfa-2a (peginterferon), for a finite duration, in a randomized trial (Source: Gastroenterology)
Source: Gastroenterology - October 7, 2015 Category: Gastroenterology Authors: Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, Florin A. Caruntu, Won Young Tak, Magdy Elkashab, Wan-Long Chuang, Seng-Gee Lim, Fehmi Tabak, Rajiv Mehta, Joerg Petersen, Graham R. Foster, Lillian Lou, Eduardo B. Martins, Phillip Dinh, Lanjia Lin, Amoreena C Source Type: research
Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B
Quantitative serum HBsAg at week 48 and HBsAg level combined with HBeAg loss at week 72 of treatment can predict sustained virological response (SVR) to 96 weeks extended therapy with Peginterferon for chronic hepatitis B patients with poor response to the initial 48 weeks of Peginterferon treatment. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - October 3, 2015 Category: Virology Authors: Jie Chen, Dong-Hua Zhang, Cheng-Run Xu, Ming-Yu Zhu, Zhi-Tao Yang, Qi-Ming Gong, De-Min Yu, Xin-Xin Zhang Source Type: research
Thyroid dysfunction in Chinese hepatitis C patients: Prevalence and correlation with TPOAb and CXCL10.
CONCLUSION: Lower pretreatment serum CXCL10 levels are associated with TD, and TD prevalence increases in female patients and patients who are positive for TPOAb at baseline.
PMID: 26361424 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - September 7, 2015 Category: Gastroenterology Authors: Zhang RW, Shao CP, Huo N, Li MR, Xi HL, Yu M, Xu XY Tags: World J Gastroenterol Source Type: research
